1. Home
  2. SLDP vs ARVN Comparison

SLDP vs ARVN Comparison

Compare SLDP & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$2.43

Market Cap

463.5M

Sector

Energy

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.96

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
ARVN
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
463.5M
516.2M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SLDP
ARVN
Price
$2.43
$8.96
Analyst Decision
Strong Buy
Buy
Analyst Count
2
19
Target Price
$7.00
$15.05
AVG Volume (30 Days)
3.9M
835.4K
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
5.56
58.84
EPS
N/A
1.70
Revenue
$21,747,000.00
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$48.90
N/A
P/E Ratio
N/A
$5.28
Revenue Growth
7.98
N/A
52 Week Low
$1.98
$6.74
52 Week High
$8.86
$14.22

Technical Indicators

Market Signals
Indicator
SLDP
ARVN
Relative Strength Index (RSI) 55.77 61.46
Support Level $2.21 $7.90
Resistance Level $2.51 $9.65
Average True Range (ATR) 0.13 0.39
MACD 0.05 0.09
Stochastic Oscillator 93.00 62.11

Price Performance

Historical Comparison
SLDP
ARVN

About SLDP Solid Power Inc.

Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: